Public Sensationalism and Clinical Trials: How to Address the Challenges of Science?

American Journal of Medicine

Volumn 123, Issue 6, 2010, Pages 481-483

  Ohman, E Magnus ^a   Roe, Matthew T ^a   Armstrong, Paul W ^b   Fox, Keith A ^c   Prabhakaran, Dorairaj ^d   White, Harvey D ^e  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF ALBERTA   (Canada)

^c ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^d CENTRE FOR CHRONIC DISEASE CONTROL   (India)

^e AUCKLAND CITY HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; EZETIMIBE; PRASUGREL; SIMVASTATIN;

ACUTE CORONARY SYNDROME; CANCER DIAGNOSIS; CLINICAL STUDY; CLINICAL TRIAL; DRUG SAFETY; EDITORIAL; HUMAN; HYPOTHESIS; PATIENT SAFETY; PRACTICE GUIDELINE; PRIORITY JOURNAL; SCIENCE;

ACCESS TO INFORMATION; CLINICAL TRIALS AS TOPIC; CONFIDENTIALITY; HUMANS;

EID: 77953230062     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2009.12.012     Document Type: Editorial

References (6)

1. DAMOCLES Study Group, NHS Health Technology Assessment Programme. A proposed charter for clinical trial data monitoring committees: helping them to do their job well. Lancet 365 (2005) 711-722
2. Califf R.M., Harrington R.A., and Blazing M.A. Premature release of data from clinical trials of ezetimibe. N Engl J Med 361 (2009) 712-717
3. Wiviott S.D., Braunwald E., McCabe C.H., et al., TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357 (2007) 2001-2015
4. Available at: www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drug s/CardiovascularandRenalDrugsAdvisoryCommittee/ucm129219.pdf. Accessed March 2010.
5. Serebruany V.L. Platelet inhibition with prasugrel and increased cancer risks: potential causes and implications. Am J Med 122 (2009) 407-408
6. Peppercorn J., Buss W.G., Fost N., and Godley P.A. The dilemma of data-safety monitoring: provision of significant new data to research participants. Lancet 371 (2008) 527-529